JCT  Vol.2 No.4 , October 2011
I-131 MIBG Therapy for Advanced Stage III & IV Neuroblastoma
Abstract: Radio-labelled MIBG therapy has been tried in the treatment of advanced stage III and IV neuroblastoma in an attempt to improve patients outcome. The use of radiolabelled MIBG to treat neuroblastoma has arisen from the high sensitivity and specificity of in vivo MIBG imaging for detection of primary and metastatic tumours. Although, clinical trials have been performed to determine the role of MIBG therapy, the overall therapeutic strategy of MIBG therapy is not precisely defined. Aim of the work: to determine the impact of MIBG therapy on patients’ outcome especially their quality of life. Patients & methods: 42 paediatri neuroblastoma patients are included in this study, 12 (28.5%) stage III disease and 30 (71.5%) stage IV. I-131 MIBG doses ranged from 100 to 150 mCi with number of courses ranged from 1-8 according to response and toxicity. Results: Group I (stage III): 1/12 patients showed complete response, 5/12 patients had partial response and the other 6 patients remained stable. The 5 years event free survival (EFS) of stage III patients was 46.6% and the overall survival was 75%. Group II (stage IV): 2/30 patients achieved CR, 9/30 patients showed PR to I-131 MIBG and the other 18 remained stable. The 5 years event free survival (EFS) of stage IV patients was 48.2% and the overall survival was 69%. Conclusion: We conclude that 131I-MIBG therapy has favourable therapeutic effects that are translated into an overall improved outcome with good quality of life.
Cite this paper: nullR. Riad, M. Kotb, W. Omar, A. Zaher, E. Ebied, A. Pitman and H. Dayem, "I-131 MIBG Therapy for Advanced Stage III & IV Neuroblastoma," Journal of Cancer Therapy, Vol. 2 No. 4, 2011, pp. 481-489. doi: 10.4236/jct.2011.24065.

[1]   G. M. Brodeur and J. M. Maris, “Neuroblastoma,” In: P. A. Pizzo and D. G. Poplack, Eds., Principles and Practice of Pediatric Oncology, Lippincott Williams & Wilkins, Philadelphia, 2006, pp. 933-970.

[2]   K. Oberg, “Advances in Chemotherapy and Biotherapy of Endocrine Tumors,” Current Opinion in Oncology, Vol. 10, No. 1, 1998, pp. 58-65. doi:10.1097/00001622-199801000-00010

[3]   W. J. Oyen, L. Bodei, F. Giammarile, H. R. Maecke, J. Tennvall, M. Luster and B. Brans, “Targeted Therapy in Nuclear Medicine—Current Status and Future Prospects,” Annals of Oncology, Vol. 18, No. 11, 2007, pp. 1782-1792. doi:10.1093/annonc/mdm111

[4]   M. Miano, A. Garaventa, et al., “Megatherapy Combining I(131) Metaiodobenzylguanidine and High-Dose Chemotherapy with Haematopoietic Progenitor Cell Rescue for Neuroblastoma,” Bone Marrow Transplant, Vol. 27, 2001, pp. 571-574.

[5]   J. De Kraker, C. A. Hoefnagel, H. Caron, et al., “First Line Targeted Radiotherapy, a New Concept in the Treatment of Advanced Stage Neuroblastoma,” European Journal of Cancer, Vol. 31, No. 4, 1995, pp. 600-602. doi:10.1016/0959-8049(95)00063-O

[6]   S. S. Goldberg, K. DeSantes, J. P. Huberty, et al., “Engraftment after Myeloablative Doses of 131I-Metaiodobenzylguanidine Followed by Autologous Bone Marrow Transplantation for Treatment of Refractory Neuroblastoma,” Medical and Pediatric Oncology, Vol. 30, No. 6, 1998, pp. 339-346. doi:10.1002/(SICI)1096-911X(199806)30:6<339::AID-MPO7>3.0.CO;2-F

[7]   C. A. Hoefnagel, P. A. Voute, J. de Kraker and H. R. Marcuse, “Radionuclide Diagnosis and Therapy of Neural Crest Tumors Using Iodine-131 Metaiodobenzylguanidine,” Journal of Nuclear Medicine, Vol. 28, 1987, pp. 308-314.

[8]   C. A. Hoefnagel, J. De Kraker, R. A. Valdes Olmos and P. A. Voute, “131I-MIBG as a First-Line Treatment in High-Risk Neuroblastoma Patients,” Nuclear Medicine Communications, Vol. 15, No. 9, 1994, pp. 712-717. doi:10.1097/00006231-199409000-00008

[9]   S. Meller, “Targeted Radiotherapy for Neuroblastoma,” Archives of Disease in Childhood, Vol. 77, 1997, pp. 389-391. doi:10.1136/adc.77.5.389

[10]   G. M. Brodeur, J. Pritchard, F. Berthold, et al., “Revisions of the International Criteria for Neuroblastoma Diagnosis, Staging and Response to Treatment,” Journal of Clinical Oncology, Vol. 11, 1993, pp. 1466-1477.

[11]   A. Garaventa, B. De Bernardi, C. Pianca, et al., “Localized but Unresectable Neuroblastoma: Treatment and Outcome of 145 Cases,” Journal of Clinical Oncology, Vol. 9, 1993, pp. 1770-1779.

[12]   G. M. Haase, J. B. Atkinson, D. O. Stram, J. N. Lukens and K. K. Matthay, “Surgical Management and Outcome of Locoregional Neuroblastoma: Comparison of the Children Cancer Group and the International Staging System,” Journal of Pediatric Surgery, Vol. 30, No. 2, 1995, pp. 289-295. doi:10.1016/0022-3468(95)90576-6

[13]   T. Philip, R. Ladenstein, C. Lasset, et al., “1070 Myeloablative Megatherapy Procedures Followed by Stem Cell Rescue for Neuroblastoma: 17 Years of European Experience and Conclusions,” European Journal of Cancer, Vol. 33, No. 12, 1997, pp. 2130-2135. doi:10.1016/S0959-8049(97)00324-9

[14]   W. Weber, J. Weber and R. Senekowitsch-Schmidtke, “Therapeutic Effect of M-[I-131]- and M-[I-125] Iodobenzylguanidine on Neuroblastoma Multicellular Tumor Spheroids of Different Sizes,” Cancer Research, Vol. 56, 1996, pp. 5428-5434.

[15]   D. Schwabe, St. Sahm, V. Gerein, et al., “131-Metaiodobenzylguanidine Therapy of Neuroblastoma in Childhood,” European Journal of Pediatrics, Vol. 146, No. 3, 1987, pp. 246-250. doi:10.1007/BF00716467

[16]   T. Klingebiel, J. Treuner, G. Ehninger, et al., “[I-131]-Metaiodobenzylguanidine in the Treatment of Metastatic Neuroblastoma,” Cancer Chemotherapy and Pharmacology, Vol. 25, No. 2, 1989, pp. 143-148. doi:10.1007/BF00692356

[17]   L. S. Lashford, I. J. Lewis, S. L. Fielding, et al., “Phase I/II Study of Iodine 131 Metaiodobenzylguanidine in Chemoresistant Neuroblastoma: A United Kingdom Children Cancer Study Group Investigation,” Journal of Clinical Oncology, Vol. 10, 1992, pp. 1889-1896.

[18]   E. J. Van Hasselt, H. A. Heij, J. De Kraker, A. Vos and P. A. Voute, “Pretreatment with [I-131]Metaiodobenzylguanidine and Surgical Resection of Advanced Neuroblastom,” European Journal of Pediatric Surgery, Vol. 6, No. 3, 1996, pp. 155-159. doi:10.1055/s-2008-1066495

[19]   R. Mastrangelo, A. Tornesello and S. Mastrangelo, “Role of 131 Metaiodobenzylguanidine in the Treatment of Neuroblastoma,” Medical and Pediatric Oncology, Vol. 31, No. 1, 1998, pp. 22-26. doi:10.1002/(SICI)1096-911X(199807)31:1<22::AID-MPO5>3.0.CO;2-1

[20]   A. Garaventa, O. Bellagamba, M. S. Lo Piccolo, et al., “I-131 Metaiodobenzylguanidine (I-131MIBG) Therapy for Residual Neuroblastoma: A Mono-Institutional Experience with 43 Patients,” British Journal of Cancer, Vol. 81, No. 8, 1999, pp. 1378-1884.